Diffuse midline glioma H3K27M mutation in adult: A case report.
Brain tumor
Diffuse midline glioma
Glioma
H3 K27 M mutation
Neurosurgical biopsy
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
02
02
2022
revised:
30
03
2022
accepted:
31
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Diffuse midline glioma with H3 K27M mutation is a new tumor entity from 2016 which is highly aggressive and classified as a WHO Grade IV tumor regardless of histopathologic features. DMG is an aggressive tumor with a poor prognosis, predominating in children and rarely in adults. The clinicopathologic features in adults remain poorly characterized. Herein we report a case of a 28-year-old female with diffuse midline glioma with pathology confirmation of histone H3 K27M mutation presenting predominately with left upper and lower limb weakness for 3 weeks followed by an event of loss of consciousness and suspicious mass in MRI Brain/CT Brain. It was confirmed by immunoreactive H3K27M with a score of 4+ in neoplastic cells, which revealed Diffuse midline glioma, H3K27M mutant. Diffuse midline glioma with histone H3-K27M mutation recently classified CNS tumor with grade IV, including both morphologic and molecular features for diagnosis and associated with poor prognosis. We report a case of adult diffuse midline glioma with H3K27M. The prognosis of diffuse midline glioma is poor and dependents solely on H3K27M irrespective of its grade and characteristics. A comprehensive study of diffuse midline glioma on clinical, radiographic, and demographic features in adult is needed.
Identifiants
pubmed: 35495373
doi: 10.1016/j.amsu.2022.103567
pii: S2049-0801(22)00327-2
pmc: PMC9052283
doi:
Types de publication
Case Reports
Langues
eng
Pagination
103567Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Neuro Oncol. 2017 Aug 01;19(8):1127-1134
pubmed: 28201752
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2579-2584
pubmed: 32196609
Clin Neuropathol. 2021 Mar-Apr;40(2):108-117
pubmed: 33191898
Brain Pathol. 2016 Sep;26(5):569-80
pubmed: 26517431
Oncotarget. 2018 Dec 14;9(98):37112-37124
pubmed: 30647848
Sci Rep. 2020 May 20;10(1):8368
pubmed: 32433577
Int J Surg Case Rep. 2020;68:124-128
pubmed: 32145563
J Cancer Res Clin Oncol. 2019 Apr;145(4):839-850
pubmed: 30610375
Int J Surg. 2020 Dec;84:226-230
pubmed: 33181358
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931